2026 Global: Gastrointestinal Infection Testing Market-Competitive Review (2032) report
Description
The 2026 Global: Gastrointestinal Infection Testing Market-Competitive Review (2032) report features the global market size and projected growth/decline data for the period 2021 and 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Roche Diagnostics, Basel, Switzerland, is a force in gastrointestinal infection testing, delivering molecular and immunodiagnostic solutions that support centralized laboratory workflows and panel based reporting. Abbott Laboratories, Abbott Park, United States, maintains a broad portfolio of GI testing tools including immunoassay and molecular panels that are widely adopted in hospital and reference laboratories. Thermo Fisher Scientific, Waltham, United States, provides extensive molecular testing platforms and diagnostic assays that underpin syndromic GI panels and high throughput workflows. bioMérieux, Marcy Etoile, France, is renowned for its FilmArray GI Panel and companion multiplex testing capabilities, aligning turnaround with point of care and centralized laboratories. QIAGEN, Hilden, Germany, spans genetic analysis platforms with GI diagnostic panels such as QIAstat Dx, supporting rapid, portfolio wide deployment across clinical labs. DiaSorin, Saluggia, Italy, contributes immunoassay and molecular testing modalities that address enteric pathogens through integrated systems and automated workflows.
Seegene, Seoul, South Korea, is a provider of multiplex real time PCR panels for gastrointestinal pathogens, enabling syndromic coverage and delivery across labs and clinical settings. Meridian Bioscience, Cincinnati, United States, supplies GI testing solutions that combine molecular panels and immunoassay assays to support routine clinical workflows. Luminex Corporation, Austin, United States, employs multiplexing technology to support GI pathogen panels and high throughput analysis for reference laboratories and public health laboratories. Eurofins Scientific, Luxembourg City, Luxembourg, operates a network of diagnostic laboratories and offers GI pathogen testing services and in house assay development. Together, these players broaden assay formats from nucleic acid amplification to immunodiagnostics and expand geographic reach across developed and emerging markets. These firms collectively drive innovation in assay sensitivity and multiplexing capacity, accelerate adoption of rapid diagnostics in inpatient and outpatient settings, and support global surveillance programs for enteric pathogens. Geographic breadth, regulatory alignment, and ongoing portfolio expansion through collaborations and acquisitions further shape their market position.
The concentration of these ten companies spans North America, Europe, and Asia, reflecting a market that prioritizes accurate detection of enteric pathogens. Their combined portfolios address a spectrum of diagnostics from immunoassays and point of care tests to high throughput molecular panels, facilitating optimized patient management, antimicrobial stewardship, and surveillance of outbreaks. Regulatory harmonization and reimbursement dynamics across regions influence product adoption and laboratory workflows, while ongoing investments in automations, data analytics, and companion software enhance result interpretation and lab efficiency. The interplay of large, diversified diagnostics groups with specialized GI assay developers underpins a market characterized by refresh cycles, frequent launches of syndromic panels, and expanding access in high-resource and emerging health systems. As gastrointestinal infections persist as major health challenges, the actions of Roche, Abbott, Thermo Fisher, bioMérieux, QIAGEN, DiaSorin, Seegene, Meridian Bioscience, Luminex, and Eurofins collectively shape diagnostic capabilities, clinical outcomes, and surveillance.
Roche Diagnostics, Basel, Switzerland, is a force in gastrointestinal infection testing, delivering molecular and immunodiagnostic solutions that support centralized laboratory workflows and panel based reporting. Abbott Laboratories, Abbott Park, United States, maintains a broad portfolio of GI testing tools including immunoassay and molecular panels that are widely adopted in hospital and reference laboratories. Thermo Fisher Scientific, Waltham, United States, provides extensive molecular testing platforms and diagnostic assays that underpin syndromic GI panels and high throughput workflows. bioMérieux, Marcy Etoile, France, is renowned for its FilmArray GI Panel and companion multiplex testing capabilities, aligning turnaround with point of care and centralized laboratories. QIAGEN, Hilden, Germany, spans genetic analysis platforms with GI diagnostic panels such as QIAstat Dx, supporting rapid, portfolio wide deployment across clinical labs. DiaSorin, Saluggia, Italy, contributes immunoassay and molecular testing modalities that address enteric pathogens through integrated systems and automated workflows.
Seegene, Seoul, South Korea, is a provider of multiplex real time PCR panels for gastrointestinal pathogens, enabling syndromic coverage and delivery across labs and clinical settings. Meridian Bioscience, Cincinnati, United States, supplies GI testing solutions that combine molecular panels and immunoassay assays to support routine clinical workflows. Luminex Corporation, Austin, United States, employs multiplexing technology to support GI pathogen panels and high throughput analysis for reference laboratories and public health laboratories. Eurofins Scientific, Luxembourg City, Luxembourg, operates a network of diagnostic laboratories and offers GI pathogen testing services and in house assay development. Together, these players broaden assay formats from nucleic acid amplification to immunodiagnostics and expand geographic reach across developed and emerging markets. These firms collectively drive innovation in assay sensitivity and multiplexing capacity, accelerate adoption of rapid diagnostics in inpatient and outpatient settings, and support global surveillance programs for enteric pathogens. Geographic breadth, regulatory alignment, and ongoing portfolio expansion through collaborations and acquisitions further shape their market position.
The concentration of these ten companies spans North America, Europe, and Asia, reflecting a market that prioritizes accurate detection of enteric pathogens. Their combined portfolios address a spectrum of diagnostics from immunoassays and point of care tests to high throughput molecular panels, facilitating optimized patient management, antimicrobial stewardship, and surveillance of outbreaks. Regulatory harmonization and reimbursement dynamics across regions influence product adoption and laboratory workflows, while ongoing investments in automations, data analytics, and companion software enhance result interpretation and lab efficiency. The interplay of large, diversified diagnostics groups with specialized GI assay developers underpins a market characterized by refresh cycles, frequent launches of syndromic panels, and expanding access in high-resource and emerging health systems. As gastrointestinal infections persist as major health challenges, the actions of Roche, Abbott, Thermo Fisher, bioMérieux, QIAGEN, DiaSorin, Seegene, Meridian Bioscience, Luminex, and Eurofins collectively shape diagnostic capabilities, clinical outcomes, and surveillance.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
